Actively Recruiting
Phase III Study of ONT01 with Gemcitabine and Nab-paclitaxel as Second-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
Led by Washington University School of Medicine · Updated on 2026-05-19
61
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether ONT01, a medication that targets the tumor environment, can help overcome resistance to checkpoint immunotherapy in people with metastatic pancreatic ductal adenocarcinoma PDAC that cannot be removed by surgery. This open-label phase III trial evaluates ONT01 combined with standard chemotherapy drugs gemcitabine and nab-paclitaxel as a second-line treatment after disease progression or intolerance to initial therapy. Participants will receive ONT01 orally twice daily on Days 1 to 21 of each 28-day cycle, with doses determined during the phase I portion. Gemcitabine and nab-paclitaxel will be given intravenously on Days 1, 8, and 15 per standard care. The trial has three arms phase I dose de-escalation with ONT01 plus chemotherapy, phase II experimental arm with ONT01 plus chemotherapy, and phase II control arm with chemotherapy alone. Throughout the study, participants will be monitored for safety and treatment effects including dose-limiting toxicities, progression-free rate at 6 months, adverse events, response rates, and survival outcomes. Assessments will be conducted during and after treatment cycles, with follow-up lasting up to 18 months. The study aims to identify a recommended phase II dose and evaluate the combination therapys impact on disease control and patient survival.
CONDITIONS
Brief Title
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Research Team
P
Patrick Grierson, M.D., Ph.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here